5. Magnetic Resonance Imaging (MRI): MRI scan pröthɛtë derɛ luäk kɛ ɣöö ba ŋɔak tin /ci̱ rɔ̱ lot ŋa̱c kɛnɛ ɣöö derɛ ji̱ek kɛ ɣöö ba ŋɔak thɛm.
6. Gɛnɛmik Thɛm: Tha̱a̱ŋ ki̱mni̱ dɔ̱ŋ bi̱ kɛn thɛmni̱ gɛnɛmik la̱t kɛ ɣöö ba luäk kɛ ŋäc kä ɣöö bɛ tekɛ juey mi̱ di̱i̱t kä ba ji̱ek kɛ kui̱i̱ kä ɣöö ba ji̱ek kɛ kui̱i̱ kä ɣöö ba ji̱ek kɛ kui̱i̱dɛ.
7. Kɔnthɛrɛn: Kɔnthɛrɛn dɔ̱ŋ ba la̱t kɛ ɣöö ba guic mi ci kanthɛr däk kä cɔ̱w.
8.Kɔmpi̱e̱tɛd Tömögi̱ra̱pi̱ (CT) Thɛn: Kɔmpi̱e̱tɛd Tömögi̱ra̱pi̱ dɔ̱ŋ ba jɛ la̱t kɛ ɣöö ba guic mi̱ ci̱ kanthɛr däk kä cuŋ pua̱a̱ny tin kɔ̱ŋ kiɛ jua̱th tin kɔ̱ŋ.
Jɛn ɛ mi̱ di̱i̱t ɛn ɣöö ba ŋa̱c ɛn ɣöö /ci̱kɛ wutni̱ diaal tin te kɛ pek mi̱ di̱i̱t kä PSA kiɛ tin /ci̱ pekdiɛn ro̱ŋ kä DRE bi̱ kɛn tekɛ kanthɛr pröthɛta, kä /ci̱kɛ kanthɛr pröthɛta diaal bi̱ kɛn pek PSA jakä di̱t.
Min dɔ̱ŋ, ɛn ca̱r in görkɛ kɛ ɣöö ba pua̱ny ran thɛm la̱tkɛ jɛ kɛ kɔr kä mi ca min ca jek kä thëmni̱ ti̱ti̱ kɛnɛ tin go̱o̱r raan kɛ kui̱ jua̱thädɛ kɛnɛ tin go̱o̱rɛ.
Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.
Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.
Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.
Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.
McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.
An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.
[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.
Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.
['Lät kɛ kui̱i̱ jua̱thni̱']
['Ɛn wɛbthaay ɛmɛ ca la̱th lät kɛ kui̱ ŋi̱i̱cä kɛnɛ läri kä /cɛ lot ni ɣöö ba ji̱ moc kɛ luäk ki̱mä kiɛ lät ti̱ gööl.']
['Lät kɛ läri tin ca ŋun /ca kɛ bi̱ lät kɛ ɣöö ba jua̱th jek kiɛ ba kɛ ciɛŋ, kä nɛy tin görkɛ luäk ki̱mädiɛn kärɔ̱ ba kɛ thiec kä ki̱m mi̱ tekɛ luäk ki̱mä.']
['Guic ɛ gɔaa ɛn ɣöö ɛn neural net min jak luɔc kä thie̱cni̱, /cɛ thuɔ̱k ɛlɔ̱ŋ mi̱ ci̱ ben kä nämbäri̱ tin te thi̱n. cetkɛ pek nath tin ca jek kɛ juey mi̱ rɛlrɔ.']
['Ni ciaŋ go̱ri ruac kä ki̱mdu kiɛ ram in kɔ̱ŋ mi ŋäc luäk pua̱a̱ny kɛ kui̱ jua̱thdu. /Cu ruac ki̱mdu car kiɛ jääny kɛ go̱ri kɛ kui̱ kä mi ci kuɛn kä wɛbthaay ɛmɛ. Mi caari jɛ ɛn ɣöö deri tekɛ juey mi go̱o̱ri luäk, cɔl 911 kiɛ wër guäth in thia̱k kɛ ji kɛ pɛ̈th. /Thilɛ maar kam ki̱m kɛnɛ juey mi bi̱ tuɔɔk kɛ kui̱ kä wɛbthaay ɛmɛ kiɛ la̱tdɛ. /Ci̱ BioMedLib kiɛ la̱a̱tkɛ, kiɛ ram in gɔ̱a̱r kɛ kui̱ kä wɛbthaay ɛmɛ, bi̱ ruac lat, kiɛ bi̱ ruac lat, kɛ kui̱ läri tin ca ka̱m raar rɛydɛ kiɛ la̱tdɛ.']
['Lät kɛ: ŋuɔ̱t']
['Ɛn Digital Millennium Copyright Act 1998, 17 U.S.C. § 512 (ɛ DMCA) ɛ ŋuɔ̱t mi̱ ŋun ji̱ cuŋni̱ tin ŋääth kɛn ɣöö ci̱ ŋɔaani̱ tin te kä intɛrnɛt ŋuɔ̱tkiɛn to̱l kɛ kui̱ ŋuɔ̱tni̱ cuŋni̱ tin te kä U.S.']
['Mi ca ji̱ ŋäth kɛ thuɔ̱k ɛn ɣöö tëëkɛ mi̱ ca gɔ̱r kiɛ mi̱ ca ka̱m ji̱ rɛy wɛbthaayäda kiɛ lät tin kɔ̱ŋ tin ci̱ ŋuɔ̱t tin ca gɔ̱r ya̱r, ji̱n (kiɛ ram in lät kɛ kui̱du) deri̱ kɔ jäk kä warɛgak mi̱ bi̱ ji̱ thiec ɛn ɣöö ba min ca gɔ̱r kiɛ min ca gɔ̱r woc, kiɛ ba duɔ̱ɔ̱r la̱t kɛ ɣöö bi̱ ji̱ cop thi̱n.']
['Kɛn läri̱ ba kɛ jäk kɛ wargak ɛ la i̱thtäm (guic ni̱ gua̱th in ci̱ i̱thtäm in ca gɔ̱r "Kɔntak" kɛ kui̱ i̱thtäm in ci̱ jäk).']
['DMCA go̱o̱rɛ ɣöö bi̱ ji̱n warɛgakdu lat kɛ kui̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä mat thi̱n kɛ läär ti̱ti̱: (1) latdɛ kɛ kui̱i̱ la̱t in ca gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä min ca lar i̱ ca gɛr; (2) latdɛ kɛ kui̱i̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛnɛ läär ti̱ ro̱ŋ kɛ ɣöö bi̱ kɔn kɛ jek; (3) läri̱ kɛ kui̱i̱ kä min dëë ji̱ luäk kɛ jek, amäni̱ ci̱ötdu, nämbärɛ kä tin ci̱ ji̱ luäk kɛ jek, kɛnɛ emaildu; (4) latdu kɛ ɣöö ci̱ ji̱n ɛ ŋa̱c ɛn ɣöö min ca gɔ̱r kɛ kui̱i̱ kä tin ca lar /ci̱kɛ bi̱ lät kɛ luäkdɛ ɛ gua̱n ŋuɔ̱tni̱ gɔ̱rä, kiɛ ɛ la̱tdɛ, kiɛ kɛ luäk ŋuɔ̱tni̱; ']
['(5) mi ci ji gɔr piny kɛ kuic kä ɣöö bi ji ruac kɛ thuɔ̱k, ɛn ɣöö läri tin ca gɔr ɛ thuɔ̱k kä te ji kɛ lua̱ŋ kɛ ɣöö bi yiöw tin ca gɔr piny tin ca lar ɛ ji̱n ka̱m raar;']
['kɛnɛ (6) mi̱ ca gɔ̱r piny ɛ gua̱n ŋuɔ̱tni̱ kiɛ ram mi̱ tekɛ lua̱ŋ kɛ lät kɛ kui̱dɛ.']
['Mi /kenɛ läri tin ca lat nhial diaal mat thi̱n dɔ̱ŋ derɛ ku lɛ wɔ̱ jɔ̱ɔ̱r kɛ lätni̱ kɛ kɛ.']
['Röm kɛ jɛ']
['Thiecɛ kɔ kɛ email kɛ thiecni kiɛ cär.']
How is prostate cancer diagnosed?
Prostate cancer is diagnosed through a combination of tests and procedures, which may include:
1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.
2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.
Elevated PSA levels may indicate the presence of prostate cancer.
3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.
This can help identify any abnormalities in the prostate gland.
4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.
This is the only definitive way to diagnose prostate cancer.
5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.
6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.
7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.
8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.
It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.
Therefore, a biopsy is necessary to confirm the diagnosis.
Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Kɛ kui̱']
['BiöMedLib lät kɛ kɔmpi̱e̱tɛri̱ tin lät kärɔ̱ (algorithmi̱ni̱ tin ŋi̱e̱e̱e̱c kɛ makanɛ) kɛ ɣöö ba thie̱e̱cni̱ kɛnɛ luɔcdiɛn kulɛ jiek.']
['Kɔn cua tok kɛ mi̱lli̱ön 35 kä baömedikal publi̱kecin PubMed/Medline. Kä bä, webpage duŋ RefinedWeb.']
